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ABSTRACT The two cysteine residues (Cys-35 and Cys-84) of bovine cardiac troponin C (cTnC) were labeled with the
pyrene-containing SH-reactive compounds, N-(1-pyrene) maleimide, and N-(1-pyrene)iodoacetamide in order to study
conformational changes in the regulatory domain of cTnC associated with cation binding and cross-bridge attachment. The
labeled cTnC exhibits the characteristic fluorescence spectrum of pyrene with two sharp monomer fluorescence peaks and one
broad excimer fluorescence peak. The excimer fluorescence results from dimerization of adjacent pyrene groups. With metal
binding (Mg2" or Ca2+) to the high affinity sites of cTnC (sites Ill and IV), there is a small decrease in monomer fluorescence but no
effect on excimer fluorescence. In contrast, Ca2+ binding to the low affinity regulatory (site 11) site elicits an increase in monomer
fluorescence and a reduction in excimer fluorescence. These results can be accounted for by assuming that the pyrene attached to
Cys-84 is drawn into a hydrophobic pocket formed by the binding of Ca2+ to site 11. When the labeled cTnC is incorporated into the
troponin complex or substituted into cardiac myofibrils the monomer fluorescence is enhanced while the excimer fluorescence is
reduced. This suggests that the association with other regulatory components in the thin filament might influence the proximity (or
mobility) of the two pyrene groups in a way similar to that of Ca2+ binding. With the binding of Ca2+ to site lI the excimer fluorescence
is further reduced while the monomer fluorescence is not changed significantly. In myofibrils, cross-bridge detachment (5 mM
MgATP, pCa 8.0) causes a reduction in monomer fluorescence but has no effect on excimer fluorescence. However, saturation of
the cTnC with Ca2+ reduces excimer fluorescence but causes no further change in monomer fluorescence. Thus, the pyrene
fluorescence spectra define the different conformations of cTnC associated with weak-binding, cycling, and rigor cross-bridges.
INTRODUCTION
Contraction in vertebrate cardiac and skeletal muscles is
initiated by the interaction of Ca2" with the regulatory
proteins in the thin filament: tropomyosin (Tm)1 and the
troponin complex (Tn) (1, 2). The troponin complex is
composed of three subunits: a Ca2' binding subunit,
troponin C (TnC), a tropomyosin binding subunit, tropo-
nin T (TnT), and an inhibitory subunit, troponin I (TnI).
Upon activation Ca2' binds to its receptor, TnC, and this
leads to a conformational changes in regulatory and
contractile proteins. It is thought that Ca2' binding
strengthens the TnC-TnI interaction and weakens the
TnI-actin interaction, thus, relieving the inhibition of
actomyosin ATPase and triggering contraction (3-5).
The TnC subunits in both cardiac (cTnC) and skeletal
(sTnC) muscle contain four potential Ca2' binding sites,
'Abbreviations: Tm, tropomyosin; Tn, troponin complex; TnC, tropo-
nin C; TnT, troponin T; TnI, troponin I; cTnC, cardiac troponin C;
sTnC, skeletal troponin C; PM, N-(1-pyrene)maleimide; PIA, N-(1-
pyrene)iodoacetamide; PM-cTnC, pyrene maleimide labeled cTnC;
PIA-cTnC, pyrene iodoacetamide-labeled cTnC; DTT, dithiothreitol;
MOPS, 3-(N-morpholino)propanesulfonic acid; EGTA, [ethylene-
bis(oxyethyleneitrilo)]tetraacetic acid; CDTA, trans-1,2-cyclohexanedi-
amine-N,N,N',N'-tetraacetic acid; Tris, tris(hydroxymethyl) ami-
nomethane.
sites I and II in the NH2-terminal domain, and sites III
and IV in the COOH-terminal domain (6). Site I in
cTnC, however, is inactive due to some critical amino
acid substitutions (7). The Ca2" binding sites ofTnC can
be differentiated in terms of Ca2" binding affinity and
specificity. Sites I and II in sTnC (site II in cTnC) bind
Ca2+ with low affinity (K - 2 x 105 M-l) and high
specificity. Thus, they are referred to as low affinity, or
Ca2+ specific sites (8). In contrast, site III and IV in both
sTnC and cTnC bind Ca2+ with high affinity (K - 107
M-'), but also bind Mg2" (K - 2 x 103 M-'). They are
referred to as high affinity or Ca2+-Mg2+ sites. On basis of
enzymatic (8, 9), kinetic (10), and molecular genetic (11)
studies it is now accepted that the Ca2+-specific site(s) is
responsible for Ca2+-activation of contraction (9),
whereas the Ca2+-Mg2+ sites probably play a structural
role in the regulatory system (12).
The crystal structure of turkey sTnC has been deter-
mined by Herzberg and James (13). The molecule has a
dumbell-shaped structure in which two globular do-
mains communicate through a nine-turn central helix.
The NH2-terminal domain of sTnC contains the two
Ca2+-specific sites, whereas the COOH-terminal domain
contains the two Ca2+-Mg2+ sites. The three-dimensional
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structure of cTnC has not been determined. However,
on the basis of sequence homology and similarities in
physiological function, it is reasonable to assume that
cTnC and sTnC have similar structures. Based on the
crystal structure of sTnC and computer modeling,
Herzberg et al. (14) proposed that when Ca2" binds to
the NH2-terminal domain, this domain assumes a confor-
mation similar to that of the COOH-terminal domain
with Ca2' bound at sites III and IV. Such a conforma-
tional transition would require a relative movement of B
and C helices as a unit away from the central helix D.
This movement would cause exposure of some hydropho-
bic amino acid side chains and form a hydrophobic
pocket around the central helix. This Ca2+-induced
formation of a hydrophobic pocket could be involved in
transmission of the activation signal from TnC to Tnl
(15, 16).
The presence of two SH groups (Cys-35 and Cys-84)
in the NH2-terminal domain of cTnC provides a means
of attaching conformational probes to this region. Cys-35
is located at nonfunctional site I, while Cys-84 is located
at the NH2-terminal segment of the central helix (helix
D) near site II. Previous studies by Ingraham and
Hodges (17) and Fuchs et al. (18) have shown that the
binding of Ca2+ to site II of cTnC causes an increased
reactivity of the SH group of Cys-84, one of the side
chains that would become more accessible to the solvent
as a result of the separation of helices C and D.
Compounds which contain the pyrene group, such as
N-(1-pyrene) maleimide (PM) and N-(1-pyrene)iodo-
acetamide (PIA) have been shown (19, 20) to be suitable
for the study of the proximity of neighboring Cys
residues. Both PM-labeled and PIA-labeled cTnC ex-
hibit a very similar emission spectrum: two sharp fluores-
cence peaks in the range from 380 to 400 nm, referred to
as monomer fluorescence and one broad fluorescence
peak in the range from 480 to 490 nm, referred to as
excimer fluorescence. The amplitude of excimer fluores-
cence reflects the tendency of two adjacent pyrene
groups to dimerize (excimer band), hence, it indicates
the ability of the two pyrene groups to approach to
within - 5 A of each other. We have labeled cTnC with
both PM and PIA because the latter is believed to cause
less disturbance to protein conformation than PM (20).
In this study, PM and PIA were used to determine
changes in the proximity of two Cys residues (Cys-35 and
Cys-84) in the regulatory region of cTnC upon Ca2+
binding and cross-bridge attachment. Previous work by
Verin and Gusev (21) with PM-labeled cTnC showed
that the pyrenes can come sufficiently close together to
provide a prominent excimer band. We have extended
this work to encompass a systematic study of pyrene
fluorescence of cTnC when alone, complexed with the
other troponin subunits, and incorporated into myo-
fibrils.
MATERIALS AND METHODS
Preparation of cardiac troponin subunits and myofibrils. All materials
were prepared from ventricles of fresh cow hearts obtained at a nearby
slaughterhouse. The purified cTnC was extracted according to Szyn-
kiewicz et al. (22). cTnI and cTnT, prepared according to Potter (23),
were a gift from Drs. Z. Grabarek and P. C. Leavis (Boston Biomedical
Research Institute). The myofibrils were prepared according to Solaro
et al. (24).
Reagents and solutions. PM and PIA (Molecular Probes, Eugene,
OR) were dissolved in dimethyl formamide and stored in a dark
container at -20°C. Fresh solutions were prepared weekly. Free Ca2"
concentrations in EGTA buffers were calculated on the basis of
absolute binding constants tabulated by Fabiato and Fabiato (25).
Calculation was carried out with the computer program EQCAL
(Biosoft, Cambridge, UK).
Modification of cardiac troponin C. The purified cTnC was treated
with dithiothreitol (DTT) in the presence of 8 M urea, 10 mM MOPS
(pH 7.0), 100 mM KCl, and 2 mM EGTA, followed by exhaustive
dialysis. The procedure for reducing SH groups of cTnC was described
previously (18). The fully reduced cTnC was reacted with a fivefold
molar excess of PM or PIA in the presence of 8 M urea (pH 7.0) for
4-5 h or overnight. The reaction was terminated with excess DTT. The
latter was removed by solvent exchange with Centricon 10 (Amicon
Corp., Danvers, MA) ultrafiltration cells. The proteins were then
dialyzed against 6 M urea, 10mM MOPS (pH 7.0), 100 mM KCI, and 2
mM EGTA at 4°C. The dialysis against the same buffer without urea
was repeated twice. For the PM-labeled cTnC, it was further treated
with 8 M urea in alkaline solution (pH 8.4) at room temperature to
cleave the succinimido ring (19). The protein was then dialyzed against
10 mM MOPS (pH 7.0), 100 mM KCI, and 2 mM EGTA. The
concentration of labeled cTnC was determined by the bicinchoninic
acid reagent (Pierce, Rockford, IL), using bovine serum albumin as a
standard (26). The amount of PM and PIA bound to cTnC was
determined on the basis of extinction coefficients at 345 nm of 23,000
and 24,800 M-'cm-' for PM-labeled and PIA-labeled cTnC, respec-
tively (19, 20). The labeling ratio of pyrene to cTnC was in the range of
1.9-2.1 for the samples used in this study.
Complexation of labeled-cTnC with cTnI, and cTnT. The pyrene-
labeled cTnC was complexed with cTnC and cTnT by mixing equimo-
lar amounts of each subunit in 6 M urea, 2.1 mM Ca2", 2 mM EGTA,
100 mM KCI, 1 mM DTT, and 10 mM MOPS (pH 7.0), to a final
concentration of 8 ,uM (27). The protein complex was incubated at
room temperature for 3 h and was then dialyzed against a solution
containing 6 M urea, 0.1 mM free Ca2", 0.1 mM DTT, 100 mM KCl,
and 10 mM MOPS, pH 7.0 at 4°C. The dialysis was then repeated twice
against 10 mM MOPS (pH 7.0), 100mM KCI, and 2 mM EGTA.
Extraction of cTnC from intact myofibrils. The endogenous cTnC of
bovine cardiac myofibrils was extracted with a solution containing 5
mM CDTA, 40 mM Tris buffer, pH 8.4, according to Morimoto and
Ohtsuki (28, 29). The degree of extraction was determined by alkaline
urea-polyacrylamide gel electrophoresis and loss of Ca2"-activated
ATPase activity.
Reinsertion of native and labeled cTnC into CDTA-treated myofibrils.
Native or pyrene-labeled cTnC was mixed with extracted myofibrils in
a ratio of 7 ,ug cTnC per mg myofibril protein. The myofibrils were
suspended in 100 mM MOPS (pH 2.0), 90 mM KCl, 5 mM MgCl2, and
2 mM EGTA. After incubation for 20 min, the myofibrils were centri-
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fuged at 2000 g to remove free cTnC. The pellet was suspended in the
same buffer and the centrifugation repeated once more.
Electrophoresis. The cTnC content of myofibrils was estimated by
alkaline urea polycrylamide gel electrophoresis, as described by
Blanchard and Solaro (30). Gels were stained with Coomassie Blue
according to the one-step procedure of Zehr et al. (31).
A TPase activity. The Ca2+-sensitive ATPase activity of myofibrils was
determined in the presence of 100 mM MOPS (pH 7.0), 90 mM KCl, 5
mM Mg2+, 2 mM EGTA, and additions as indicated. The temperature
was maintained at 30°C. The reaction was started by the addition of
MgATP to a concentration of 1 mM and terminated after 10 min by the
addition of an equal volume of 2% SDS (15). The mixture was then
analyzed for inorganic phosphate (32).
Spectrofluorimetry. Fluorescence measurements were carried out
at room temperature with a SPEX Fluorolog 2 spectrofluorimeter
(SPEX Industries, Edison NJ). For cTnC in solution the labeled-
protein (0.5 ,uM) was dissolved in 100 mM MOPS (pH 7.0), 50 mM
KCI, and 2 mM EGTA, with additions as indicated. The solution was
excited at 345 nm and the fluorescence emission was scanned from 360
to 580 nm. Solutions (volume 1 ml) were placed in a semi-micro cell
and Ca2+ titrations were carried out by adding with a digital micro-
pipet aliquots of a commercial standard solution (Radiometer) of
0.1 M CaCl2. Total volume change did not exceed 2% and in the
presence of 100 mM MOPS the pH change was too small to require
correction. For fluorescence measurements on myofibril suspensions
the solvent composition was the same and the protein composition was
adjusted to 0.1-0.5 mg/ml. These measurements were carried out in a
3.5 ml cell (1 cm square) with constant stirring.
RESULTS
Effects of Mg2+ and Ca2+ binding on PM-cTnC and
PL4-cTnC. Both PM-cTnC and PIA-cTnC, in the ab-
sence of divalent cations, exhibited very similar fluores-
cence emission spectra: two sharp monomer fluores-
cence peaks at 385 and 405 nm and a broad excimer
fluorescence peak with a maximum at 490 nm (Fig. 1).
Thus, in accord with previous data (21), there are no
apparent restrictions on the ability of the two pyrene
groups to dimerize in the metal-free state. Upon addi-
tion of 5 mM Mg2e the monomer fluorescence was
reduced by 5-10 and 20-25% in PM-cTnC and PIA-
cTnC, respectively, whereas there was hardly any effect
on excimer fluorescence. Addition of sufficient
Ca2+(pCa 6) to saturate the two Ca2+-Mg2+ sites
produced the same effect. This result suggests that
cation binding (Mg2+ or Ca2+) at the high affinity sites of
the COOH-terminal domain affects the environment of
the probes attached at the two SH groups in the NH2
terminal domain, possibly through a direct contact
between the two domains in solution at physiological pH
(33). However, the average distance between the two
pyrenes does not seem to change. In contrast, the
binding of Ca2' at the low affinity site of pyrene-labeled
cTnC(pCa 5.5-4.0) caused an increase in monomer
fluorescence and a decrease in excimer fluorescence
(Figs. 2 and 3).
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FIGURE 1 Effect of Mg2" on fluorescence emission spectra of PM-
cTnC and PIA-cTnC. Solutions contained 0.5 ,uM cTnC, 50 mM KCl,
100 mM MOPS (pH 7.0), and 2 mM EGTA. (Curve 1), No Mg2";
(curve 2), 5 mM Mg2'.
Based on x-ray diffraction data obtained with turkey
sTnC (13, 14) Cys-35 and Cys-84 should be separated by
-20 A. The reduction in excimer fluorescence associ-
ated with Ca2' binding at site II would suggest that Ca2+
binding induces a substantial separation of the two Cys
residues. We have carried out fluorescence resonance
energy transfer measurements (to be published else-
where) and have obtained values of 20-23 A for the
Cys-35 to Cys-84 distance. Depending on the donor-
acceptor pair used, binding of Ca>2 to site II caused
either no change, or at most, a 1-2 A increase in
distance between the two groups. It seems doubtful that
separation of the two Cys residues would account for the
Ca2+-induced fall in excimer fluorescence. An alterna-
tive interpretation, suggested by studies of SH reactivity
(18), is that the pyrene attached to Cys-84 is immobilized
by the hydrophobic pocket formed by the binding of Ca2
to site II. This effect of Ca2 binding would also account
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TABLE i Ratios of excimer/monomer fluorescence intensities
No Mg", 5 mM Mg", 5 mM Mg",
pCa 8.0 pCa 8.0 pCa 4.0
PM-cTnC 0.48 + 0.003 0.56 ± 0.01 0.25 + 0.01
PM-cTnC-cTnI 0.29 + 0.01 0.27 + 0.003 0.10 + 0.003
PM-cTnC-cTnI-cTnT 0.29 + 0.01 0.26 + 0.004 0.10 + 0.003
Wavelength (nm)
FIGURE 2 Examples of pyrene fluorescence spectra recorded after
addition of Ca21 to produce varying pCa values as indicated. Solution
contained 50 mM KCl, 100 mM MOPS (pH 7.0), 2 mM EGTA, 5 mM
MgCl2, and 0.5 ,uM PM-cTnC.
for the observed increase in monomer fluorescence.
Qualitatively similar results were obtained with PM and
PIA. The change in excimer fluorescence upon addition
of Ca2" was of smaller magnitude with PIA-cTnC.
Complex of PM-labeled cTnC with cTnI and cTnT.
When cTnI was complexed with pyrene-labeled cTnC
the ratio of excimer fluorescence to monomer fluores-
cence was reduced (Table 1). As shown in Fig. 4, this
reduction results from both an increase in monomer
Fluorescence spectra were obtained as described in Methods. Solu-
tions contained 50 mM KCl, 100 mM MOPS (pH 7.0), 2 mM EGTA,
and additions of Mg2' and Ca2' as indicated. Each value is mean
SEM of five measurements.
fluorescence and a decrease in excimer fluorescence.
Addition of 5 mM Mg2+ to the PM-cTnC-cTnI complex
had no significant effect on the fluorescence emission
spectrum. The binding of Ca2+ to the low affinity site of
PM-cTnC complexed with cTnI elicited a significant
reduction in excimer fluorescence but had only a small
effect on the monomer fluorescence (Fig. 4). The incor-
poration of cTnT into the complex was without signifi-
cant effect. Fig. 5 shows the relative excimer and
monomer fluorescence of pyrene-labeled cTnC com-
plexed with cTnI and cTnT as a function of pCa. With an
increase in free Ca2+ there was a reduction in excimer
fluorescence but no significant change in monomer
fluorescence. The half maximal reduction in excimer
fluorescence occurred at pCa 6.5, as compared with
- 5.8 for PM-cTnC. This finding is consistent with data
showing that incorporation of cTnC into the Tn complex
leads to a significant increase in the affinity of the
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FIGURE 3 Relative monomer and excimer fluorescence of PM-cTnC and PIA-cTnC as a function of pCa. Relative fluorescence is expressed as the
ratio of monomer (at 385 nm) and excimer (at 490 nm) fluorescence peaks at a given pCa relative to that at pCa 8.0. Solution composition is as in
Fig. 2. Each point is mean ± SEM of five measurements.
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FIGURE 4 Effect of cTnI on the fluorescence emission spectrum of
PM-cTnC. Pyrene fluorescence emission spectra were recorded from
solutions of PM-cTnC and PM-cTnC-cTnI, both at 0.5 F±M. Solution
composition was as in Fig. 2. (Curve 1), PM-cTnC, pCa 8.0; (curve 2),
PM-cTnC-cTnI, pCa 8.0; (curve 3), PM-cTnC-cTnI, pCa 4.0.
regulatory site for Ca2" (9). These results indicate that
complexation with cTnI and binding of Ca2" to site II
have similar effects on the environment of the pyrene
label.
Insertion ofpyrene-labeled cTnC into myofibrils. While
several studies have focused on conformational changes
in cTnC in solution, relatively little is known about the
conformational behavior of cTnC in the intact myofibril.
Therefore, we carried out a series of studies of pyrene
fluorescence after the insertion of the modified cTnC
into myofibrils. We verified the observation of Hoar et
al. (34) that the cTnC of bovine myofibrils is highly
resistant to extraction with the usual low ionic strength
EDTA solutions. However, satisfactory extraction of
cTnC could be obtained with CDTA at pH 8.4, as
described by Morimoto and Ohtsuki (28, 29). Unex-
tracted myofibrils contained an average of 0.39 ,umol
cTnC/g myofibril protein. With the Morimoto-Ohtsuki
procedure we could routinely remove 60-90% of the
cTnC. Urea gels illustrating the removal of cTnC from
myofibrils and reinsertion of either native cTnC or
pyrene-labeled cTnC are shown in Fig. 6.
Reinsertion of pyrene-labeled cTnC into extracted
myofibrils restored Ca2+-activated ATPase activity as
effectively as native cTnC (Table 2). Thus, although
pyrene labeling may cause some loss of helical content
(21), biological activity is preserved and it would seem
reasonable to assume that the conformational changes
which promote Ca2' activation occur to the same extent
in both native and labeled cTnC.
Fluorescence emission spectra recorded with myo-
fibrils containing pyrene-labeled cTnC are shown in Fig.
7. The excimer to monomer ratio was reduced to about
the same extent as that observed when the modified
cTnC was complexed with cTnI in solution. Moreover,
123 4 5
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FIGURE 5 Relative excimer and monomer fluorescence of PM-cTnC-
cTnI and PM-cTnC-cTnI-cTnT, as a function of pCa. Solutions
contained 50 mM KCI, 100 mM MOPS (pH 7.0) 5 mM Mg2', 2 mM
EGTA, and varying Ca2+ concentrations. Subunits were present at
equimolar concentration (0.5 ,um). (E*), PM-cTnC-cTnI; (E 4),
PM-cTnC-cTnI-cTnT. Each point is mean + SEM of five measure-
ments.
FIGURE 6 Urea gels illustrating removal and reinsertion of native and
modified cTnC. (Track 1), 1 ,ug cTnC; (tracks 2-5), 100 ,ug myofibrils.
(Track 2), Unextracted myofibrils; (track 3), extracted myofibrils;
(track 4), extracted myofibrils + cTnC; (track 5), extracted myofibrils
+ PM-cTnC.
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TABLE 2 ATPase activities of control, extracted, and
reconstitued myofibrils
pCa 8.0 pCa 4.0
Control 38.0 + 2.15 83.93 ± 1.88
Extracted 38.27 ± 1.52 42.93 ± 2.02
Reconstituted with native cTnC 48.83 ± 1.63 88.23 ± 4.30
Reconstituted with PM-cTnC 49.97 ± 4.19 95.98 ± 6.04
Values are expressed as nmol Pi/mg protein/min. Each value is mean
± SEM of three measurements. See Methods for experimental details.
addition of Ca2+ sufficient to saturate site II caused a
further reduction in excimer fluorescence with little or
no effect on monomer fluorescence. If the myofibrils
were converted from the "rigor" to "relaxed" state by
the addition of 5 mM MgATP, pCa 8.0, there was a
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marked reduction in monomer fluorescence with no
effect on excimer fluorescence (Fig. 8). Elevation of the
Ca2" concentration (pCa 4.0), however, in the presence
of MgATP, reduced the excimer fluorescence, with no
further change seen in monomer fluorescence.
The data in Fig. 9 are a summary of the effects of Ca2"
on pyrene fluorescence in myofibrils in the rigor, cycling,
and relaxed states. In the cycling state Ca2" was varied in
the presence of MgATP. To produce "relaxed" myo-
fibrils, that is, myofibrils in which cross-bridge cycling
was inhibited at all pCa values, the myofibrils were
exposed to 1 mM sodium vanadate in the presence of
MgATP and Ca2", as described by Hofmann and Fuchs
(35). The data indicate that once cTnC is complexed
with cTnI, either in solution or in the myofibril, Ca2"
causes a significant reduction in excimer fluorescence,
with no significant effect on monomer fluorescence.
Furthermore, the effect on excimer fluorescence seems
to depend only on the Ca2" concentration and not on the
state of attachment of the cross-bridge. That is, Ca2"
binding produced the same reduction in excimer fluores-
cence in rigor, relaxed, and cycling myofibrils. It is of
interest that monomer fluorescence was reduced consid-
erably when myofibrils in rigor were exposed to MgATP
at pCa 8.0 and it remained at the same level even as pCa
was reduced to 4.0. Thus, rigor cross-bridges and cycling
cross-bridges seem to have different effects on the
pyrene environment.
In considering fluorescence spectra recorded from
myofibril suspensions, one must take into account possi-
Wavelength (nm)
FIGURE 8 Effect of cross-bridge state on fluorescence emission spec-
trum of myofibrils replaced with PM-cTnC. Myofibril suspensions
contained 0.5 mg/ml of myofibrils, 100 mM MOPS (pH 7.0), 90 mM
KCI, 5 mM Mg2", and 2 mM EGTA. (Curve 1), No MgATP, pCa 8.0;
(curve 2), 5 mM MgATP, pCa 8.0; and (curve 3), 5 mM MgATP, pCa
4.0.
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FIGURE 7 Effect of Ca2" on fluorescence emission spectra of CDTA-
treated myofibrils replaced with PM-cTnC or PIA-cTnC. Mixture
contained 0.5 mg/ml protein, 90 mM KCI, 100 mM MOPS (pH 7.0), 2
mM EGTA, 5 mM MgCl2, and Ca2' as indicated. (Curve 1), pCa 8.0;
(curve 2), pCa 4.0.
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FIGURE 9 Relative excimer and monomer fluorescence of PM-cTnC-
containing myofibrils in different cross-bridge states (rigor, cycling,
and relaxed) as a function of pCa. (A) No MgATP (rigor); (B) 5 mM
MgATP (cycling); (C) 5 mM MgATP and 1 mM sodium vanadate
(relaxed). Each point is mean + SEM of five measurements.
ble light scattering artifacts. We have done two sets of
experiments that seem to rule out the possibility that
light scattering phenomena have complicated our re-
sults. Firstly, if unextracted myofibrils were added to a
solution of pyrene-labeled cTnC at the concentration
used in our experiments there was no significant change
in the pyrene fluorescence spectrum. Secondly, the
pyrene-labeled myofibrils were placed in a triangular
cell to reduce optical path length to a minimum and the
intensity of the emitted light was measured at an angle
Pyrene has been shown to be a useful probe of proximity
relations between neighboring SH groups (19, 20). In
isolated cTnC at physiological pH, the pyrene groups
attached to Cys-35 and Cys-84 can come sufficiently
close together to give rise to a strong excimer peak (21).
The binding of Ca2+ or Mg2+ to sites III and IV had
virtually no effect on excimer fluorescence and caused a
variable reduction in monomer fluorescence, depending
on whether the protein was reacted with PM or PIA. On
the other hand, Ca2+ binding to the regulatory site
caused a marked reduction in excimer fluorescence and
a moderate increase in monomer fluorescence. These
results may be compared to those of Verin and Gusev
(21), who reported that both in the presence and
absence of Mg2+ reduction of pCa from 9 to 6 caused a
reduction in excimer fluorescence and an increase in
monomer fluorescence. In the pCa range 6-4 the exci-
mer fluorescence was unchanged while the monomer
fluorescence decreased slightly. Verin and Gusev (21)
interpreted their data as indicating that the major effect
on the pyrene fluorescence spectrum was due to the
binding of Ca2' at sites III and IV. Our data are more
consistent with a site II-mediated change in the fluores-
cence spectrum. We have no obvious explanation for this
discrepancy. Conceivably, there may have been differ-
ences in pCa or pH buffering that might account for a
shift in the pCa axis. In any case, our results are
consistent with data showing that fluorescence probes
attached to the NH2-terminal domain of cTnC or sTnC
are most sensitive to Ca2' binding at the NH2-terminal
domain, especially in the presence of Mg2+ (11, 27).
The decrease in excimer fluorescence associated with
Ca2' binding to site II clearly indicates that there must
have been a separation of the two pyrene groups. Such a
separation might imply that the two Cys residues have
moved further apart but, as pointed out above, distance
measurements made by fluorescence resonance energy
transfer do not provide strong support for this hypothe-
sis. A more likely possibility, also alluded to by Verin
and Gusev (21), is that one of the pyrenes, probably the
one at Cys-84, is drawn into a hydrophobic pocket
formed when Ca2+ binding at site II induces a movement
of helix C away from the central helix. Movement of this
pyrene into a more hydrophobic environment would also
account for the increase in monomer fluorescence. We
assume that the pyrene attached to Cys-35 does not
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undergo any change in its environment. Support for this
assumption comes from the recent work of Putkey et al.
(37) with a genetically-engineered mutant of cTnC
having only the single cysteine at position 35. A fluores-
cent molecule attached to Cys-35 undergoes no change
in emission when Ca2" binds to site II.
Complexation of pyrene-labeled cTnC with cTnI
caused the monomer fluorescence to increase and the
excimer fluorescence to decrease, in agreement with
Verin and Gusev (21). Titration with Ca2' resulted in a
further reduction in excimer fluorescence but no addi-
tional change in monomer fluorescence. It would appear
that cTnI, in the absence of Ca2 , causes the NH2-
terminal domain to assume a conformation intermediate
between the "relaxed" and "Ca2+-activated" states.
Consistent with this interpretation is the observation of
Ingraham and Hodges (17) that complexation of cTnI
with cTnC causes an increased reactivity of the Cys-84 of
cTnC. The reactivity of Cys-84 is enhanced even further
by the addition of Ca2+ to the complex. This result might
suggest that even in the absence of Ca2 , cTnI can cause
some exposure of hydrophobic side chains, sufficient to
account for both a decrease in excimer fluorescence and
an increase in Cys-84 reactivity. Studies with skeletal
muscle proteins (38) have established that the inhibitory
region of sTnI can interact with sTnC in the NH2-
terminus (helix C), central helix, and COOH-terminus
(helix G). Only COOH-terminal interaction is Ca2+
independent. It has been suggested that the binding of
Ca2+ to the regulatory sites allows a portion of sTnI to
bind to the hydrophobic patch formed by the movement
of helices B and C (15, 16). Whether this model applies
in every detail to cardiac muscle remains to be deter-
mined. If so, it would appear that the COOH-terminal
attachment alone must be able to cause significant
displacement of helices B and C away from the central
helix. The fact that monomer fluorescence in the PM-
cTnC-cTnI complex is unchanged upon the binding of
Ca2+ may be attributed to the effect of cTnI on Ca2+
binding loop I. Putkey et al. (37) showed that when the
mutant cTnC containing only Cys-35 is labeled with a
fluorescent probe and complexed with cTnI, the binding
of Ca2+ at site II caused a decrease in fluorescence
emission. We would suggest that the lack of effect of
Ca2+ on the monomer fluorescence of the cTnC-cTnI
complex reflects the opposite responses of the two
pyrenes. Studies with pyrene-labeled mutants should
provide more definitive evidence on this point.
When the modified cTnC is inserted into myofibrils
the response to Ca2+ is very similar to that seen in the
cTnC-cTnI complex or the troponin complex. That is,
monomer fluorescence is relatively unchanged and exci-
mer fluorescence is further decreased by 40-50% as the
myofibrils are titrated with Ca2+. Half-maximal decrease
in excimer fluorescence occurs at pCa 6.6-6.8. What is
consistently different is that that excimer fluorescence
begins to fall at a higher pCa, giving the impression that
under these conditions excimer fluorescence may be
influenced by binding at the high affinity sites. Such an
interpretation would be premature in the light of evi-
dence that in an intact system with cross-bridges present,
there is no simple relationship between the Ca2" sensitiv-
ity of the fluorescence response and the affinity of Ca2"
for specific binding sites. This is reflected in studies of
sTnC labeled at Met-25 with dansylaziridine, a fluores-
cence probe that monitors Ca2' binding in the NH2-
terminal domain of sTnC. Thus, when dansylaziridine-
labeled sTnC is inserted into skinned rabbit psoas fibers,
the fluorescence-pCa curve is shifted considerably to the
left of the force-pCa curve (39, 40). In fact, in this system
the cross-bridge interactions themselves make a larger
contribution to the fluorescence response than Ca2+
binding; even "weak-binding" nonforce generating cross-
bridges induce a substantial fluorescence emission (40).
Morano and Ruegg (40) suggest that at low Ca2+
concentrations there may be enough weak binding
cross-bridges formed to produce an increase in fluores-
cence (or in this case a decrease in excimer fluores-
cence) without any tension development.
The studies with sTnC cited above have emphasized
the reciprocal effects of Ca2' binding and cross-bridge
attachment on sTnC conformation and drawn attention
to the idea that there may be several different conforma-
tional states of the troponin C subunit (41). Such
reciprocal interactions also occur in cardiac muscle, as
evidenced by studies showing the enhancement of Ca2+-
cTnC affinity with cross-bridge attachment (35). Of
interest in this regard are the data in Fig. 8, showing that
when rigor cross-bridges are converted to weak binding
cross-bridges (5 mM MgATP, pCa 8.0) there is a
decrease in monomer fluorescence with no change in
excimer fluorescence. However, when Ca2+ was added to
saturate the regulatory site, the excimer fluorescence
decreased but the monomer fluorescence remained at
the same level as at pCa 8.0. Thus, the fluorescence
spectra characterize three different conformations corre-
sponding to weak-binding cross-bridges, cycling cross-
bridges, and rigor cross-bridges. The fall of excimer
fluorescence seems to signal the conformational change
that is coupled to Ca2' activation of cross-bridge cycling.
As shown in Fig. 9, the extent of this change seems to be
independent of the state of the cross-bridges. Based on
data cited above it is tempting to attribute the fall in
excimer fluorescence to an immobilization of the pyrene
at Cys-84 by the hydrophobic pocket formed when helix
C moves away from the central helix.
The data show that rigor cross-bridges and cycling
cross-bridges have different conformational effects on
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cTnC, despite the fact that both types of attachments
produce about the same increase in Ca2+-cTnC affinity
(35, 42). The nature of this difference remains to be
determined. It is also puzzling that the transition from
rigor to the weak binding state caused a fall in monomer
fluorescence with no change in excimer fluorescence.
Evidently, one or the other of the pyrenes moved into a
less hydrophobic environment yet the ability of the two
pyrenes to dimerize has not changed. Further structural
studies will be needed to provide a more complete
picture of the behavior of the pyrene groups both in
solution and in the intact myofibril.
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